CHOSOURCE Expression Platform
Freedom of expression: Robust performance without constraints
The CHOSOURCE™ expression platform provides an enhanced CHO host cell line for the development and manufacturing of biotherapeutics. It consists of the CHO-K1 suspension adapted cell line with the Glutamine Synthetase gene (GS) knocked out (KO) to provide a robust CHO cell line development system.
From early research to commercial production, the CHOSOURCE expression platform helps you streamline cell line development, improve productivity, and accelerate programs.
This proven CHO expression system delivers robust performance for stable cell line development backed by flexible licensing terms, full traceability, and compatibility with existing workflows - so that you're in control.
Our experienced global support team is on-hand to provide expert advice, information, and technical support for our CHOSOURCE expression platform and cell line engineering services, supporting you through adoption and as your biotherapeutic development needs evolve.
100+
regulatory
filings
100+
licensees
4
market
authorizations
2L to 2,000L
excellent
scalability
Contact our team to find the best solution for your cell line development needs.
Key Benefits of the CHOSOURCE Expression Platform
You can address key challenges in therapeutic antibody production with the CHOSOURCE expression platform:
- De-risk regulatory filings: With over 100 successful regulatory filings, at least 4 market authorisations with regulatory agencies across the world and a Drug Master File (DMF) filed with the US-FDA, our proven documentation smooths clinical approval processes.
- Take control: We have confidence in the robust performance of our platform, so as a licensee you can have the freedom to use it as you need for your processes, without restrictions on the use of expression plasmids or media source, and without CDMO transfer fees.
- Accelerate timelines: Our stable platform helps de-risk the later stages of development, enabling early downstream process optimisation, formulation, and toxicological studies.
CHOSOURCE GS KO cell line: Confidence of a well-established CHO cell line
The CHOSOURCE Glutamine Synthetase (GS) knockout (KO) cell line is a well-established, cGMP-manufactured, robust GS knockout CHO cell line. It is generated from CHO-K1 cells with the GS gene knocked out using precision rAAV technology.
With proven performance, the CHOSOURCE GS KO cell line comes with a comprehensive cell history package and protocols to support you throughout the process of research, development, regulatory filing, and manufacturing biotherapeutics.
CHOSOURCE ADCC+ cell line: Increase control over potency and efficacy
The glycoengineered CHOSOURCE GS KO cell line for enhanced antibody-dependent cellular cytotoxicity (ADCC) activity offers fully afucosylated antibodies, Fc-fusions, and other therapeutic proteins for increased therapeutic efficacy and potency.
Experience full control over biopharmaceutical potency with the CHOSOURCE ADCC+ cell line. Developed from the CHOSOURCE GS KO cell line, this stable cell line provides controlled product quality (100% fucose-free) and expanded therapeutic applications by enhancing the therapeutic window and broadening the patient population.
CHOSOURCE TnT transposon technology: Accelerate biotherapeutics development
The CHOSOURCE TnT transposon expression system offers a safe and reliable technology for the generation of stable expressing clones. This system provides faster development timelines and high reproducibility across pools and clones to help accelerate CHO cell line development programs.
The two-component CHO expression system, which includes the TnT transposon plasmid and TnT transposase mRNA, is optimized for use with CHOSOURCE cell lines.
The robustness and reliability of CHOSOURCE TnT technology make it a powerful tool for streamlining biotherapeutic development and manufacturing processes, with the potential to enable new paradigms that can expedite preclinical and clinical development.
Bioproduction Cell Line Engineering Services: Optimize product quality with our trusted team
Partner with our gene editing experts to aid your biotherapeutic development with custom editing of bioproduction cell lines. We're able to support your specific manufacturing needs for protein and viral vector therapeutics with over 10 years of experience in gene editing for biotherapeutic manufacturing.
Benefit from an advanced CRISPR-based platform suitable for commercial applications, multiple editing capabilities, and fully traceable documented history.
CHOSOURCE customer testimonials
The CHOSOURCE expression platform has been licensed globally over 100 times, ranging from academia to large pharma and biotech, as well as small to large CDMOs. Hear how some of these customers implemented the CHOSOURCE platform, how the platform can be tailored to meet their unique needs, and the flexible licensing terms to their specific requirements.
CHOSOURCE Certified Program
CHOSOURCE™ certified program for CDMO licensees provides Revvity’s attestation of your expertise using the CHOSOURCE platform to help you stand out from the crowd.
The CHOSOURCE™ Platform is available for research, clinical, diagnostic, and commercialization applications, including services, under specific licenses from Revvity.
Featured resources
FAQs
-
What is the CHOSOURCE platform?
The CHOSOURCE™ Platform is a CHO‑based expression system, providing robust scalable performance for regulatory‑ready biotherapeutic cell line production. It includes GS knockout CHO cell lines, afucosylated ADCC⁺ variants, and a transposon‑based TnT system for stable cell line development.
-
How does the CHOSOURCE platform compare to other CHO expression systems?
The CHOSOURCE platform offers a tried and tested path to stable cell line development when compared to many other CHO systems. It combines engineered CHO cell lines, a transposon‑based integration system, and a standardized workflow that helps reduce variability and accelerate development timelines. The result is a platform that supports high productivity, robust performance, scalability, and smoother progression from research to commercial manufacturing.
It has a strong regulatory record with over 100 global filings, a Drug Master File (DMF) filed with the US-FDA and at least 4 market authorisations, providing a level of confidence and de‑risking potential regulatory hurdle during product approval.
Other key differences valued by drug developers and CDMOs is the support of our dedicated team and our flexible licensing with no constraints on the use of expression plasmid or media source and no CDMO transfer fees - giving them greater control over their budget and pipeline.
-
Is the CHOSOURCE platform suitable for commercial manufacturing?
Yes, the CHOSOURCE platform is suitable for commercial manufacturing. It was developed specifically to support end‑to‑end biotherapeutic production, from early research through large‑scale GMP operations.
Our stable cell lines have a well‑established regulatory history, with more than 100 global filings and at least 4 market authorisations. They are designed for robustness, high productivity, and consistency across pools and clones. This makes the CHOSOURCE platform an ideal fit for companies looking to streamline development timelines while maintaining the quality and reliability required for commercial supply.
-
What licensing options are available for the CHOSOURCE platform?
We work with you to craft a flexible license that meets your specific business needs, whether that’s to support your research activities or an expanding pipeline of products in clinical development.
Our robust platform combined with our flexible licensing options give you the freedom you need to stay in control. Options include a license without restrictions on the use of expression plasmids or media source, flexible application, no CDMO transfer fees, and the ability to raise multiple regulatory filings and in multiple jurisdictions at no additional cost.
Please contact our team for further information and to discuss your needs
